Effect of high-potency cannabis on corpus callosum microstructure
- PMID: 26610039
- PMCID: PMC4754829
- DOI: 10.1017/S0033291715002342
Effect of high-potency cannabis on corpus callosum microstructure
Abstract
Background: The use of cannabis with higher Δ9-tetrahydrocannabinol content has been associated with greater risk, and earlier onset, of psychosis. However, the effect of cannabis potency on brain morphology has never been explored. Here, we investigated whether cannabis potency and pattern of use are associated with changes in corpus callosum (CC) microstructural organization, in patients with first-episode psychosis (FEP) and individuals without psychosis, cannabis users and non-users.
Method: The CC of 56 FEP (37 cannabis users) and 43 individuals without psychosis (22 cannabis users) was virtually dissected and segmented using diffusion tensor imaging tractography. The diffusion index of fractional anisotropy, mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity was calculated for each segment.
Results: Across the whole sample, users of high-potency cannabis had higher total CC MD and higher total CC AD than both low-potency users and those who never used (p = 0.005 and p = 0.004, respectively). Daily users also had higher total CC MD and higher total CC AD than both occasional users and those who never used (p = 0.001 and p < 0.001, respectively). However, there was no effect of group (patient/individuals without psychosis) or group x potency interaction for either potency or frequency of use. The within-group analysis showed in fact that the effects of potency and frequency were similar in FEP users and in users without psychosis.
Conclusions: Frequent use of high-potency cannabis is associated with disturbed callosal microstructural organization in individuals with and without psychosis. Since high-potency preparations are now replacing traditional herbal drugs in many European countries, raising awareness about the risks of high-potency cannabis is crucial.
Keywords: Cannabis; corpus callosum; first-episode psychosis; tractography; white matter.
Figures
Comment in
-
Skunk-like cannabis may damage white matter in the brain, study shows.BMJ. 2015 Nov 26;351:h6417. doi: 10.1136/bmj.h6417. BMJ. 2015. PMID: 26613612 No abstract available.
Similar articles
-
An MRI study of white matter tract integrity in regular cannabis users: effects of cannabis use and age.Psychopharmacology (Berl). 2016 Oct;233(19-20):3627-37. doi: 10.1007/s00213-016-4398-3. Epub 2016 Aug 8. Psychopharmacology (Berl). 2016. PMID: 27503373
-
White matter microstructure in individuals at clinical high risk of psychosis: a whole-brain diffusion tensor imaging study.Schizophr Bull. 2014 Jul;40(4):895-903. doi: 10.1093/schbul/sbt079. Epub 2013 Jun 4. Schizophr Bull. 2014. PMID: 23737549 Free PMC article.
-
White Matter Microstructural Abnormalities in the Broca's-Wernicke's-Putamen "Hoffman Hallucination Circuit" and Auditory Transcallosal Fibers in First-Episode Psychosis With Auditory Hallucinations.Schizophr Bull. 2021 Jan 23;47(1):149-159. doi: 10.1093/schbul/sbaa105. Schizophr Bull. 2021. PMID: 32766733 Free PMC article.
-
Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.Lancet Psychiatry. 2016 Mar;3(3):215-25. doi: 10.1016/S2215-0366(15)00363-6. Epub 2016 Jan 15. Lancet Psychiatry. 2016. PMID: 26777297 Review.
-
The Role of the Corpus Callosum (Micro)Structure in Bimanual Coordination: A Literature Review Update.J Mot Behav. 2023;55(5):525-537. doi: 10.1080/00222895.2023.2221985. Epub 2023 Jun 19. J Mot Behav. 2023. PMID: 37336516 Review.
Cited by
-
Impact of cannabis use on brain metabolism using 31P and 1H magnetic resonance spectroscopy.Neuroradiology. 2023 Nov;65(11):1631-1648. doi: 10.1007/s00234-023-03220-y. Epub 2023 Sep 22. Neuroradiology. 2023. PMID: 37735222 Free PMC article.
-
Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studies.Front Neuroimaging. 2023 Mar 7;2:1129587. doi: 10.3389/fnimg.2023.1129587. eCollection 2023. Front Neuroimaging. 2023. PMID: 37554654 Free PMC article.
-
Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study.Cannabis. 2021 Oct 1;4(2):47-59. doi: 10.26828/cannabis/2021.02.004. eCollection 2021. Cannabis. 2021. PMID: 37287530 Free PMC article.
-
Associations of alternative cannabis product use and poly-use with subsequent illicit drug use initiation during adolescence.Psychopharmacology (Berl). 2023 Mar 3:10.1007/s00213-023-06330-w. doi: 10.1007/s00213-023-06330-w. Online ahead of print. Psychopharmacology (Berl). 2023. PMID: 36864260
-
Legalizing Harmful Drugs: Government Participation and Optimal policies.B E J Econom Anal Policy. 2022 Nov 14;23(1):113-164. doi: 10.1515/bejeap-2021-0309. eCollection 2023 Jan. B E J Econom Anal Policy. 2022. PMID: 36726404 Free PMC article.
References
-
- Acosta-Cabronero J, Williams GB, Pengas G, Nestor PJ (2010). Absolute diffusivities define the landscape of white matter degeneration in Alzheimer's disease. Brain 133, 529–539. - PubMed
-
- Annett M (1970). A classification of hand preference by association analysis. British Journal of Psychology 61, 303–321. - PubMed
-
- Arnone D, Abou-Saleh MT, Barrick TR (2006). Diffusion tensor imaging of the corpus callosum in addiction. Neuropsychobiology 54, 107–113. - PubMed
-
- Arnone D, Barrick TR, Chengappa S, Mackaya CE, Clark CA, and Abou-Saleh MT (2008). Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. NeuroImage 41, 1067–1074. - PubMed
-
- Basser PJ, Matiello J, Le Bihan D (1994). Estimation of the effective self-diffusion tensor from the NMR spin echo. Journal of Magnetic Resonance, Series B 103, 247–254. - PubMed
Publication types
MeSH terms
Grants and funding
- G0600972/MRC_/Medical Research Council/United Kingdom
- MR/J002739/1/MRC_/Medical Research Council/United Kingdom
- MR/K004867/1/MRC_/Medical Research Council/United Kingdom
- RP-PG-0606-1049/DH_/Department of Health/United Kingdom
- G108/603/MRC_/Medical Research Council/United Kingdom
- MRF_C0439/MRF/MRF/United Kingdom
- MR/K013807/1/MRC_/Medical Research Council/United Kingdom
- MR/M008436/1/MRC_/Medical Research Council/United Kingdom
- G1100583/MRC_/Medical Research Council/United Kingdom
- G0700995/MRC_/Medical Research Council/United Kingdom
- MR/N029488/1/MRC_/Medical Research Council/United Kingdom